Whole-body photobiomodulation therapy in Parkinson's disease: a single-arm feasibility and safety pilot trial with exploratory cognitive signals

Background Beyond dopaminergic loss, Parkinson's disease (PD) involves mitochondrial dysfunction, ATP/NAD⁺ depletion, neuroinflammation, and reduced cerebral perfusion. Photobiomodulation (PBM)—red and near-infrared light absorbed by mitochondrial cytochrome c oxidase—raises ATP synthesis, increases nitric-oxide–mediated blood flow, and reduces inflammation, and so could act on several of these pathways at once. In PD, PBM has been applied almost exclusively transcranially; whole-body PBM (WB-PBM) has not been evaluated. We conducted an early-phase pilot to characterise its safety, feasibility, and preliminary effects ahead of a future sham-controlled trial. Methods This single-centre, single-arm, prospective pilot trial enrolled 15 patients with idiopathic PD (Hoehn & Yahr 1–3); 14 completed 30 WB-PBM sessions (660/810/850/930 nm; skin-surface irradiance 35–65 mW/cm²; 20 min; three times weekly for 10 weeks). The pre-specified registered primary efficacy outcome was the UPDRS total score; exploratory motor and cognitive outcomes were also assessed. Pre–post changes used the Wilcoxon signed-rank test (effect size r = Z/√N), with Benjamini–Hochberg false-discovery-rate (FDR) correction applied within a pre-specified memory family (SVLT, RCFT). Results The registered primary outcome, UPDRS total, fell from 24.86 ± 15.98 to 20.29 ± 8.71—a moderate-sized reduction (r = − 0.42) that did not reach significance in this small sample (p = 0.127). Within the memory family, verbal learning improved with a large effect and survived FDR correction: SVLT total score (r = − 0.74; p = 0.006; p_adj = 0.041) and its constituent immediate recall (r = − 0.69; p = 0.009; p_adj = 0.041). Visuospatial memory (RCFT immediate recall, delayed recall, total score) also improved with large effects, significant before but not after correction (all p_adj = 0.076). Motor outcomes were maintained without deterioration. One participant had mild localised hyperpigmentation, judged unrelated to the study device and resolving during the study; no serious adverse events occurred. Conclusions WB-PBM was safe and feasible in PD. Verbal memory improved robustly enough to survive FDR correction, visuospatial memory showed a promising signal requiring confirmation, and the registered primary outcome showed a non-significant, moderate-sized reduction. A sham-controlled randomised trial should follow. Trial registration ClinicalTrials.gov, NCT07271927 (https//clinicaltrials.gov/study/NCT07271927) registered 9 December 2025 retrospectively registered (first participant enrolled 12 February 2025).

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-18
DOI
https://doi.org/10.21203/rs.3.rs-10677352/v1
Primary Topic
Laser Applications in Dentistry and Medicine
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Whole-body photobiomodulation therapy in Parkinson's disease: a single-arm feasibility and safety pilot trial with exploratory cognitive signals

Ji Soo Baik, Jae‐Hyeok Lee, Yong Il Shin, Sung Youn Lee et al.
3 links
Research Square
Laser Applications in Dentistry and Medicine
preprint

Whole-body photobiomodulation therapy in Parkinson's disease: a single-arm feasibility and safety pilot trial with exploratory cognitive signals

Ji Soo Baik, Jae‐Hyeok Lee, Yong Il Shin, Sung Youn Lee, Cherrie Ahn
preprint en

Abstract

Background Beyond dopaminergic loss, Parkinson's disease (PD) involves mitochondrial dysfunction, ATP/NAD⁺ depletion, neuroinflammation, and reduced cerebral perfusion. Photobiomodulation (PBM)—red and near-infrared light absorbed by mitochondrial cytochrome c oxidase—raises ATP synthesis, increases nitric-oxide–mediated blood flow, and reduces inflammation, and so could act on several of these pathways at once. In PD, PBM has been applied almost exclusively transcranially; whole-body PBM (WB-PBM) has not been evaluated. We conducted an early-phase pilot to characterise its safety, feasibility, and preliminary effects ahead of a future sham-controlled trial. Methods This single-centre, single-arm, prospective pilot trial enrolled 15 patients with idiopathic PD (Hoehn & Yahr 1–3); 14 completed 30 WB-PBM sessions (660/810/850/930 nm; skin-surface irradiance 35–65 mW/cm²; 20 min; three times weekly for 10 weeks). The pre-specified registered primary efficacy outcome was the UPDRS total score; exploratory motor and cognitive outcomes were also assessed. Pre–post changes used the Wilcoxon signed-rank test (effect size r = Z/√N), with Benjamini–Hochberg false-discovery-rate (FDR) correction applied within a pre-specified memory family (SVLT, RCFT). Results The registered primary outcome, UPDRS total, fell from 24.86 ± 15.98 to 20.29 ± 8.71—a moderate-sized reduction (r = − 0.42) that did not reach significance in this small sample (p = 0.127). Within the memory family, verbal learning improved with a large effect and survived FDR correction: SVLT total score (r = − 0.74; p = 0.006; p_adj = 0.041) and its constituent immediate recall (r = − 0.69; p = 0.009; p_adj = 0.041). Visuospatial memory (RCFT immediate recall, delayed recall, total score) also improved with large effects, significant before but not after correction (all p_adj = 0.076). Motor outcomes were maintained without deterioration. One participant had mild localised hyperpigmentation, judged unrelated to the study device and resolving during the study; no serious adverse events occurred. Conclusions WB-PBM was safe and feasible in PD. Verbal memory improved robustly enough to survive FDR correction, visuospatial memory showed a promising signal requiring confirmation, and the registered primary outcome showed a non-significant, moderate-sized reduction. A sham-controlled randomised trial should follow. Trial registration ClinicalTrials.gov, NCT07271927 (https//clinicaltrials.gov/study/NCT07271927) registered 9 December 2025 retrospectively registered (first participant enrolled 12 February 2025).

Research Square
Kyung Hee University (KR), Pusan National University Yangsan Hospital (KR), Pusan National University (KR)
Pusan National University, Kyung Hee University
Good health and well-being
Laser Applications in Dentistry and Medicine
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon